---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-005100"
form_type: "8-K"
ticker: "CNBX"
cik: "0001343009"
company_name: "CNBX Pharmaceuticals Inc."
filed_at: "2022-07-25T23:59:59+00:00"
generated_at: "2026-06-24T09:05:40.527243+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CNBX appoints Dr. Sanja Goldberg as CTO, replacing Dr. Eyal Ballan

## Summary
- Dr. Eyal Ballan resigned as CTO and employment ended effective July 20, 2022.
- Dr. Sanja Goldberg appointed as new CTO on July 24, 2022.
- Goldberg previously held senior researcher roles at Sheba Medical Center's Cancer Research Lab.
- She held executive positions at Compugen and TaGeza Biopharma (VP R&D).
- Goldberg earned a Ph.D. in Cell Biology from Erasmus MC, Rotterdam in 2009.

## SEC filing metadata
- accession: 0001683168-22-005100
- form_type: 8-K
- ticker: CNBX
- cik: 0001343009
- company_name: CNBX Pharmaceuticals Inc.
- filed_at: 2022-07-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/0001683168-22-005100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/cnbx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-005100
- JSON: https://secwatch.observer/filing/0001683168-22-005100.json
- Plain text: https://secwatch.observer/filing/0001683168-22-005100.txt

## Key facts
- Executive change
  Sanja Goldberg was appointed as Chief Technology Officer at CNBX Pharmaceuticals Inc..
  - Action: appointed
  - Role: Chief Technology Officer
  source text: Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24 th , 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/0001683168-22-005100-index.htm
- Executive change
  Eyal Ballan resigned as Chief Technology Officer at CNBX Pharmaceuticals Inc..
  - Action: resigned
  - Role: Chief Technology Officer
  source text: Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20 th , 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1343009/000168316822005100/0001683168-22-005100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.